GALACTIC - GALACTIC
Contribution To Literature:
The GALACTIC trial failed to show that early/sustained vasodilatation was superior to standard of care.
Description:
The goal of the trial was to evaluate early/sustained vasodilatation compared with standard of care among patients with acute decompensated heart failure.
Study Design
- Randomized
- Parallel
A total of 781 patients with acute heart failure were randomized to early intensive and sustained vasodilatation (nitrates, hydralazine, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker, sacubitril/valsartan) vs. standard of care. Both groups received loop diuretics, beta-blockers, aldosterone antagonists, cardiac devices, and routine follow-up.
Inclusion criteria:
- Patients presenting to the emergency department with acute decompensated heart failure
- New York Heart Association (NYHA) class III-IV symptoms
- Elevated natriuretic peptides
- Systolic blood pressure ≥100 mm Hg
Principal Findings:
The primary outcome, death or acute heart failure rehospitalization at 180 days, occurred at a similar frequency between groups (hazard ratio 1.07, p = 0.59).
Interpretation:
Among patients with acute decompensated heart failure, early/sustained vasodilatation did not reduce mortality or rehospitalization for heart failure compared with standard of care.
References:
Presented by Dr. Christian Eugen Mueller at the European Society of Cardiology Congress, Paris, France, September 2, 2019.
Keywords: ESC 19, ESC Congress, Adrenergic beta-Antagonists, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Emergency Service, Hospital, Heart Failure, Hydralazine, Mineralocorticoid Receptor Antagonists, Natriuretic Peptides, Nitrates, Sodium Potassium Chloride Symporter Inhibitors, Standard of Care, Vasodilation
< Back to Listings